Article Text

Download PDFPDF
Time for a prospective study to evaluate the Amber Care Bundle
  1. David C Currow1 and
  2. Irene Higginson2
  1. 1Discipline, Palliative and Supportive Services, Flinders University, Adelaide, South Australia, Australia
  2. 2Department of Palliative Care and Rehabilitation, King's College, London, UK
  1. Correspondence to Professor David Currow, Discipline, Palliative and Supportive Services, Health Sciences Building, Repatriation General Hospital, Daws Road, Daw Park, SA 5041, Australia; david.currow{at}, David.Currow{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Amber Care Bundle

Any new intervention will have benefits and burdens, some of which will be predictable and others unpredictable. Therefore, it is imperative that all new interventions are evaluated within a stringent framework to understand both the benefits and harms. The predictable effects must be measured prospectively, and the population who experience any adverse outcomes characterised in order to refine the use of the intervention. Once harms are identified, if they are unable to be mitigated then they can have risk management plans put in place or focus the intervention only on specific sub-populations who do not experience identified harms. Unpredictable harms need to be sought vigilantly and characterised in frequency and magnitude.

This approach is commonly applied to new medicines and increasingly to non-pharmacological treatments including new and modified systems of care. Unfortunately, robust evaluations of such complex interventions such as systems of care, care …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.